Trial Profile
A Randomized Phase 2 Study of Human Anti-PDGFRa Monoclonal Antibody (IMC-3G3) With Paclitaxel/Carboplatin or Paclitaxel/Carboplatin Alone in Previously Untreated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Olaratumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 26 Jun 2018 Status changed from active, no longer recruiting to completed.
- 12 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 03 May 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.